NEW YORK (GenomeWeb News) – A new company spun out of the National University of Singapore (NUS) launched today with a technology that it said can instantly provide a diagnosis for gastric and esophageal cancers during endoscopy.

The company, Endofotonics, is further developing the in-vivo molecular diagnostic (IMDX) system for a commercial launch, possibly by 2018, according to its Co-founder and CEO Florence Leong.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.